GPC1 Specific CAR-T Cells Eradicate Established Solid Tumor Without Adverse Effects and Synergize with Anti-PD-1 Ab

Overview

Journal Elife

Specialty Biology

Date 2020 Apr 2

PMID 32228854

Citations 34

Authors

Daiki Kato

Tomonori Yaguchi

Takashi Iwata

Yuki Katoh

Kenji Morii

Kinya Tsubota

Yoshiaki Takise

Masaki Tamiya

Haruhiko Kamada

Hiroki Akiba

Kouhei Tsumoto

Satoshi Serada

Tetsuji Naka

Ryohei Nishimura

Takayuki Nakagawa

Yutaka Kawakami

Affiliations

Soon will be listed here.

Abstract

Current xenogeneic mouse models cannot evaluate on-target off-tumor adverse effect, hindering the development of chimeric antigen receptor (CAR) T cell therapies for solid tumors, due to limited human/mouse cross-reactivity of antibodies used in CAR and sever graft-versus-host disease induced by administered human T cells. We have evaluated safety and antitumor efficacy of CAR-T cells targeting glypican-1 (GPC1) overexpressed in various solid tumors. GPC1-specific human and murine CAR-T cells generated from our original anti-human/mouse GPC1 antibody showed strong antitumor effects in xenogeneic and syngeneic mouse models, respectively. Importantly, the murine CAR-T cells enhanced endogenous T cell responses against a non-GPC1 tumor antigen through the mechanism of antigen-spreading and showed synergistic antitumor effects with anti-PD-1 antibody without any adverse effects in syngeneic models. Our study shows the potential of GPC1 as a CAR-T cell target for solid tumors and the importance of syngeneic and xenogeneic models for evaluating their safety and efficacy.

Citing Articles

CAR-T Therapy Beyond B-Cell Hematological Malignancies.

Canichella M, de Fabritiis P Cells. 2025; 14(1.

PMID: 39791742 PMC: 11719893. DOI: 10.3390/cells14010041.

CAR-T cell therapy: Advances in digestive system malignant tumors.

Xu N, Wu Z, Pan J, Xu X, Wei Q Mol Ther Oncol. 2024; 32(4):200872.

PMID: 39377038 PMC: 11456800. DOI: 10.1016/j.omton.2024.200872.

Syngeneic Mouse Models for Pre-Clinical Evaluation of CAR T Cells.

Ahmed E, Cutmore L, Marshall J Cancers (Basel). 2024; 16(18).

PMID: 39335157 PMC: 11430534. DOI: 10.3390/cancers16183186.

Empowering brain tumor management: chimeric antigen receptor macrophage therapy.

Feng F, Shen J, Qi Q, Zhang Y, Ni S Theranostics. 2024; 14(14):5725-5742.

PMID: 39310093 PMC: 11413779. DOI: 10.7150/thno.98290.

Cancer therapy with antibodies.

Paul S, Konig M, Pardoll D, Bettegowda C, Papadopoulos N, Wright K Nat Rev Cancer. 2024; 24(6):399-426.

PMID: 38740967 PMC: 11180426. DOI: 10.1038/s41568-024-00690-x.

References

Jiang Z, Jiang X, Chen S, Lai Y, Wei X, Li B . Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma. Front Immunol. 2017; 7:690. PMC: 5225101. DOI: 10.3389/fimmu.2016.00690. View

Duan L, Hu X, Feng D, Lei S, Hu G . GPC-1 may serve as a predictor of perineural invasion and a prognosticator of survival in pancreatic cancer. Asian J Surg. 2012; 36(1):7-12. DOI: 10.1016/j.asjsur.2012.08.001. View

Walker A, Majzner R, Zhang L, Wanhainen K, Long A, Nguyen S . Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase. Mol Ther. 2017; 25(9):2189-2201. PMC: 5589087. DOI: 10.1016/j.ymthe.2017.06.008. View

Morgan R, Yang J, Kitano M, Dudley M, Laurencot C, Rosenberg S . Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010; 18(4):843-51. PMC: 2862534. DOI: 10.1038/mt.2010.24. View

Zhao Y, Wang Q, Yang S, Kochenderfer J, Zheng Z, Zhong X . A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol. 2009; 183(9):5563-74. PMC: 6292203. DOI: 10.4049/jimmunol.0900447. View

Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y . Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell. 2009; 15(3):195-206. DOI: 10.1016/j.ccr.2009.01.023. View

Shiina S, Ohno M, Ohka F, Kuramitsu S, Yamamichi A, Kato A . CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains. Cancer Immunol Res. 2016; 4(3):259-68. DOI: 10.1158/2326-6066.CIR-15-0060. View

Lamers C, Sleijfer S, Vulto A, Kruit W, Kliffen M, Debets R . Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol. 2006; 24(13):e20-2. DOI: 10.1200/JCO.2006.05.9964. View

Beatty G, Haas A, Maus M, Torigian D, Soulen M, Plesa G . Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014; 2(2):112-20. PMC: 3932715. DOI: 10.1158/2326-6066.CIR-13-0170. View

10.

James S, Greenberg P, Jensen M, Lin Y, Wang J, Budde L . Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation. J Immunol. 2010; 184(8):4284-94. PMC: 2896691. DOI: 10.4049/jimmunol.0903701. View

11.

Brown C, Alizadeh D, Starr R, Weng L, Wagner J, Naranjo A . Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. N Engl J Med. 2016; 375(26):2561-9. PMC: 5390684. DOI: 10.1056/NEJMoa1610497. View

12.

Amatya V, Kushitani K, Kai Y, Suzuki R, Miyata Y, Okada M . Glypican-1 immunohistochemistry is a novel marker to differentiate epithelioid mesothelioma from lung adenocarcinoma. Mod Pathol. 2018; 31(5):809-815. DOI: 10.1038/modpathol.2017.190. View

13.

Harada E, Serada S, Fujimoto M, Takahashi Y, Takahashi T, Hara H . Glypican-1 targeted antibody-based therapy induces preclinical antitumor activity against esophageal squamous cell carcinoma. Oncotarget. 2017; 8(15):24741-24752. PMC: 5421884. DOI: 10.18632/oncotarget.15799. View

14.

Matsuzaki S, Serada S, Hiramatsu K, Nojima S, Matsuzaki S, Ueda Y . Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer. Int J Cancer. 2017; 142(5):1056-1066. DOI: 10.1002/ijc.31124. View

15.

Tran E, Chinnasamy D, Yu Z, Morgan R, Lee C, Restifo N . Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med. 2013; 210(6):1125-35. PMC: 3674706. DOI: 10.1084/jem.20130110. View

16.

Rossig C, Bollard C, Nuchtern J, Rooney C, Brenner M . Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood. 2002; 99(6):2009-16. DOI: 10.1182/blood.v99.6.2009. View

17.

Carpenito C, Milone M, Hassan R, Simonet J, Lakhal M, Suhoski M . Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A. 2009; 106(9):3360-5. PMC: 2651342. DOI: 10.1073/pnas.0813101106. View

18.

Morello A, Sadelain M, Adusumilli P . Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors. Cancer Discov. 2015; 6(2):133-46. PMC: 4744527. DOI: 10.1158/2159-8290.CD-15-0583. View

19.

Ghorashian S, Kramer A, Onuoha S, Wright G, Bartram J, Richardson R . Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat Med. 2019; 25(9):1408-1414. DOI: 10.1038/s41591-019-0549-5. View

20.

Hui E, Cheung J, Zhu J, Su X, Taylor M, Wallweber H . T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017; 355(6332):1428-1433. PMC: 6286077. DOI: 10.1126/science.aaf1292. View